Relay Therapeutics Inc (RLAY) concluded trading on Wednesday at a closing price of $3.81, with 4.53 million shares of worth about $17.27 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.57% during that period and on January 15, 2025 the price saw a loss of about -12.31%. Currently the company’s common shares owned by public are about 166.89M shares, out of which, 123.45M shares are available for trading.
Stock saw a price change of -17.53% in past 5 days and over the past one month there was a price change of -20.29%. Year-to-date (YTD), RLAY shares are showing a performance of -7.52% which decreased to -65.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.00 but also hit the highest price of $11.16 during that period. The average intraday trading volume for Relay Therapeutics Inc shares is 2.09 million. The stock is currently trading -13.18% below its 20-day simple moving average (SMA20), while that difference is down -21.09% for SMA50 and it goes to -41.25% lower than SMA200.
Relay Therapeutics Inc (NASDAQ: RLAY) currently have 166.89M outstanding shares and institutions hold larger chunk of about 73.18% of that.
The stock has a current market capitalization of $637.73M and its 3Y-monthly beta is at 1.59. It has posted earnings per share of -$2.61 in the same period. It has Quick Ratio of 18.42 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RLAY, volatility over the week remained 21.83% while standing at 10.02% over the month.
Analysts are in expectations that Relay Therapeutics Inc (RLAY) stock would likely to be making an EPS of -0.55 in the current quarter, while forecast for next quarter EPS is -0.61 and it is -2.55 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.68 which is -0.39 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.67 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 9.80% while it is estimated to decrease by -4.75% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on September 10, 2024 offering a Buy rating for the stock and assigned a target price range of between $10.60 and $16 to it. Coverage by Goldman stated Relay Therapeutics Inc (RLAY) stock as a Buy in their note to investors on September 10, 2024, suggesting a price target of $20 for the stock. On September 10, 2024, Oppenheimer Downgrade their recommendations, while on May 10, 2024, Barclays Upgrade their ratings for the stock with a price target of $15. Stock get a Hold rating from Jefferies on April 20, 2023.
